An anti-inflammatory chalcone derivative prevents heart and kidney from hyperlipidemia-induced injuries by...

Area of Science:

• Biochemistry
• Cardiovascular Research
• Nephrology

Background:

• Obesity is a global pandemic characterized by lipid overload, leading to chronic inflammation.
• Inflammation in cardiac and renal tissues exacerbates damage in obese individuals.
• Previous research indicated a chalcone derivative, L6H21, inhibits inflammatory responses.

Purpose of the Study:

• To investigate the effects of L6H21 on inflammatory responses in cellular and animal models of lipid overload.
• To determine if L6H21 can mitigate inflammation and tissue damage associated with high-fat diets.
• To elucidate the underlying molecular mechanisms of L6H21's anti-inflammatory action.

Main Methods:

• Palmitic acid (PA) challenge in mouse peritoneal macrophages to assess inflammatory cytokine expression.
• Apolipoprotein E knockout (ApoE-/-) mice fed a high-fat diet (HFD) to model obesity-related injury.
• Analysis of mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NFκB) signaling pathways.
• Histological examination of kidney and heart tissues for fibrosis and inflammation.

Main Results:

• L6H21 significantly reduced PA-induced inflammatory cytokine expression in macrophages.
• L6H21 inhibited MAPK and NFκB signaling pathways in response to palmitic acid.
• In HFD-fed ApoE-/- mice, L6H21 decreased kidney and heart fibrosis and inflammatory markers.
• In vivo inhibition of MAPK and NFκB signaling pathways by L6H21 was observed.

Conclusions:

• L6H21 demonstrates potent anti-inflammatory effects in both in vitro and in vivo models of lipid overload.
• L6H21 mitigates high-fat diet-induced cardiac and renal injuries by suppressing MAPK and NFκB signaling.
• L6H21 shows potential as a therapeutic agent for obesity-related cardiovascular and kidney damage.